These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 2190927

  • 1. Prolonged duration of blood pressure response to enalkiren, the novel dipeptide renin inhibitor, in essential hypertension.
    Boger RS, Glassman HN, Cavanaugh JH, Schmitz PJ, Lamm J, Moyse D, Cohen A, Kleinert HD, Luther RR.
    Hypertension; 1990 Jun; 15(6 Pt 2):835-40. PubMed ID: 2190927
    [Abstract] [Full Text] [Related]

  • 2. Immediate blood pressure effects of the renin inhibitor enalkiren and the angiotensin-converting enzyme inhibitor enalaprilat.
    Neutel JM, Luther RR, Boger RS, Weber MA.
    Am Heart J; 1991 Oct; 122(4 Pt 1):1094-100. PubMed ID: 1656720
    [Abstract] [Full Text] [Related]

  • 3. Clinical pharmacology of enalkiren, a novel, dipeptide renin inhibitor.
    Glassman HN, Kleinert HD, Boger RS, Moyse DM, Griffiths AN, Luther RR.
    J Cardiovasc Pharmacol; 1990 Oct; 16 Suppl 4():S76-81. PubMed ID: 1705633
    [Abstract] [Full Text] [Related]

  • 4. Assessment of renin dependency of hypertension with a dipeptide renin inhibitor.
    Weber MA, Neutel JM, Essinger I, Glassman HN, Boger RS, Luther R.
    Circulation; 1990 Jun; 81(6):1768-74. PubMed ID: 2188754
    [Abstract] [Full Text] [Related]

  • 5. Effects of renin inhibition in systemic hypertension.
    Anderson PW, Do YS, Schambelan M, Horton R, Boger RS, Luther RR, Hsueh WA.
    Am J Cardiol; 1990 Dec 01; 66(19):1342-7. PubMed ID: 2244565
    [Abstract] [Full Text] [Related]

  • 6. Responses to converting enzyme and renin inhibition. Role of angiotensin II in humans.
    Fisher ND, Allan D, Kifor I, Gaboury CL, Williams GH, Moore TJ, Hollenberg NK.
    Hypertension; 1994 Jan 01; 23(1):44-51. PubMed ID: 8282330
    [Abstract] [Full Text] [Related]

  • 7. Prolonged blood pressure reduction by orally active renin inhibitor RO 42-5892 in essential hypertension.
    van den Meiracker AH, Admiraal PJ, Man in 't Veld AJ, Derkx FH, Ritsema van Eck HJ, Mulder P, van Brummelen P, Schalekamp MA.
    BMJ; 1990 Jul 28; 301(6745):205-10. PubMed ID: 2203486
    [Abstract] [Full Text] [Related]

  • 8. Haemodynamic, renal and hormonal responses to enalkiren in four patients with post-surgical oliguria.
    Jackson B, Liu G, Perich RB, Paxton D, McNicols L, Gutteridge G, Johnston CI.
    Clin Exp Pharmacol Physiol; 1994 Feb 28; 21(2):163-6. PubMed ID: 8039272
    [Abstract] [Full Text] [Related]

  • 9. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
    Dietz R, Dechend R, Yu CM, Bheda M, Ford J, Prescott MF, Keefe DL.
    J Renin Angiotensin Aldosterone Syst; 2008 Sep 28; 9(3):163-75. PubMed ID: 18957387
    [Abstract] [Full Text] [Related]

  • 10. Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of enalkiren (Abbott-64662, a new renin inhibitor). I: Single dose study.
    Gupta SK, Granneman GR, Boger RS, Hollenberg NK, Luther RR.
    Drug Metab Dispos; 1992 Sep 28; 20(6):821-5. PubMed ID: 1362933
    [Abstract] [Full Text] [Related]

  • 11. Intrarenal angiotensin II formation in humans. Evidence from renin inhibition.
    Fisher ND, Allan DR, Gaboury CL, Hollenberg NK.
    Hypertension; 1995 May 28; 25(5):935-9. PubMed ID: 7737730
    [Abstract] [Full Text] [Related]

  • 12. Renal and endocrine responses to a renin inhibitor, enalkiren, in normal humans.
    Cordero P, Fisher ND, Moore TJ, Gleason R, Williams GH, Hollenberg NK.
    Hypertension; 1991 Apr 28; 17(4):510-6. PubMed ID: 2013477
    [Abstract] [Full Text] [Related]

  • 13. Comparative effects of three different potent renin inhibitors in primates.
    Clozel JP, Fischli W.
    Hypertension; 1993 Jul 28; 22(1):9-17. PubMed ID: 8319997
    [Abstract] [Full Text] [Related]

  • 14. Hemodynamic and humoral effects of the new renin inhibitor enalkiren in normal humans.
    Delabays A, Nussberger J, Porchet M, Waeber B, Hoyos P, Boger R, Glassman H, Kleinert HD, Luther R, Brunner HR.
    Hypertension; 1989 Jun 28; 13(6 Pt 2):941-7. PubMed ID: 2661434
    [Abstract] [Full Text] [Related]

  • 15. Hemodynamic effects of renin inhibition by enalkiren in chronic congestive heart failure.
    Neuberg GW, Kukin ML, Penn J, Medina N, Yushak M, Packer M.
    Am J Cardiol; 1991 Jan 01; 67(1):63-6. PubMed ID: 1986506
    [Abstract] [Full Text] [Related]

  • 16. Renin inhibitors in hypertension.
    Luther RR, Glassman HN, Boger RS.
    Clin Nephrol; 1991 Oct 01; 36(4):181-6. PubMed ID: 1959244
    [Abstract] [Full Text] [Related]

  • 17. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.
    Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP.
    Circulation; 2005 Mar 01; 111(8):1012-8. PubMed ID: 15723979
    [Abstract] [Full Text] [Related]

  • 18. Effects of a novel renin inhibitor in patients with essential hypertension.
    Bursztyn M, Gavras I, Tifft CP, Luther R, Boger R, Gavras H.
    J Cardiovasc Pharmacol; 1990 Mar 01; 15(3):493-500. PubMed ID: 1691375
    [Abstract] [Full Text] [Related]

  • 19. Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
    Jordan J, Engeli S, Boye SW, Le Breton S, Keefe DL.
    Hypertension; 2007 May 01; 49(5):1047-55. PubMed ID: 17353513
    [Abstract] [Full Text] [Related]

  • 20. Acute inhibition of endopeptidase 24.11 in essential hypertension: SCH 34826 enhances atrial natriuretic peptide and natriuresis without lowering blood pressure.
    Richards AM, Crozier IG, Espiner EA, Ikram H, Yandle TG, Kosoglou T, Rallings M, Frampton C.
    J Cardiovasc Pharmacol; 1992 May 01; 20(5):735-41. PubMed ID: 1280735
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.